Skip to content

Clinical trials

Phase 2 Nasopharyngeal Carcinoma trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Nasopharyngeal Carcinoma Phase: Phase 2 Country / region: China Clear all

176 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20074
20083
20092
20105
20114
20125
20133
20145
20156
201610
20177
201810
201912
202014
202116
202221
20237
202413
202513
202613

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status77
Completed39
Recruiting29
Not yet recruiting14
Active, not recruiting11
Terminated3
Withdrawn2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Sun Yat-sen University65
Fudan University15
Zhejiang Cancer Hospital10
Fujian Cancer Hospital6
Jiangxi Provincial Cancer Hospital4
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4
Akeso3
Guangxi Medical University3
Ming-Yuan Chen3
Sichuan Baili Pharmaceutical Co., Ltd.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Nasopharyngeal Carcinoma176
Nasopharyngeal Neoplasms14
Recurrence11
Neoplasm Metastasis7
Stomatitis4
Carcinoma, Non-Small-Cell Lung2
Epstein-Barr Virus Infections2
Head and Neck Neoplasms2
Radiation Injuries2
Anemia1

Trials

Showing 1 to 25 of 176. Each trial links to its page on Pharma Observatory.

76 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.